General discussion, page-14650

First 14650 Last

Share
Profile

Follow
kingkev

28,075 Posts.

1408

25/11/22

09:49

Post #: 64981377
Share

Originally posted by bavarian1975: ↑

Ok just have a look at this - this is just the numbers - let this sink in... below is a table of the healthcare stocks on the ASX and their 1 year return... sorted from worst to best. Taken from.... S t o c k h e a d...
https://unauthorised investment advice/health/how-out-of-favour-biotech-has-a-pr-problem-and-could-learn-from-dr-karl/

THE NEGATIVE RETURNS

THE POSITIVE RETURNS>

SOME COMMENTS
Notice
1. How long that list was for negative returns - crazy. Do we really think all these companies are that bad? Of course not, it is just the macro affecting everything.
2. Even those at the bottom of the negative list - copping only -10-15% many of them are revenue generating (or close to) companies.
3. The positive list has 14 companies! Even then only a handful are in double digit returns. One is a multi bagger, cause it has a genuine Ph 3 and aloe to revenue.

General thoughts...
All of this is to point out simply that what is happening, is just part of the broader overall shift away from risk, from biotech in general and from non-revenue generating companies. Any company pre-clinical or pre PH2/3 is going nowhere.

Does this mean IHL have not got the goods? not at all, no doubt on the list above there will be others that will multi bag over the year. Biotechs take years to get through pH 1- 2 and IHL are going fast, it used to take decades, now it takes them a few years.

DYOR AND ALL THAT.

Expand

Thanks for this..............it explains a lot

happy accumulating..........assuming the possibilities still come. Todays ann is a good one

IHL Price at posting: 25.5¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

RBA holds rates as ALP election campaigning kicks off – expect more political focus

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

HVN

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

RCE

Recce reaches key dosing milestone in testing of skin infection gel